Q2 2024 New Drug Report (April-June)

The MyMatrixx clinical team found only one new drug approved in Q2 2024 (April through June) that may potentially be seen in workers’ compensation claims.

Libervant (diazepam) buccal film was approved by The Food and Drug Administration (FDA) on April 26, 2024 to treat seizure clusters in children aged 2 to 5 years. Libervant is a film version of diazepam, a benzodiazepine, that is placed inside the cheek to dissolve and provide a steady dose of the drug. It is used to treat acute repetitive seizures and seizure clusters, which are episodes of frequent seizure activity that are different from a patient's normal seizure pattern. Libervant is available in 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg formulations.

Beyond this new approval, there were no other generic medication releases or medication discontinuation or withdrawals during the quarter that we felt will impact our clients or the workers’ compensation industry.

The following table summarizes potential workers’ compensation prescription drug changes in the market. These could be new drug approvals, new generics, withdrawals and discontinuations of certain products, as well as near-term pipeline products and patent expirations. There may be other labeled or off-label uses for these products that may or may not be supported by medical treatment guidelines.

In some cases, there may not be an exact date listed, so the assumption would be that the approval or patent expiration would be at some point during the listed month, quarter or year. For discontinued medications, dispensing may still continue until pharmacies have exhausted their existing supply. Anticipated approval dates and availability of generics are subject to final FDA approval. Please note that these lists are not all-inclusive.

If you have any questions, please contact your Clinical Account Executive or another member of your account team.

Workers’ Compensation Prescription Drug Updates